HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inter Parfums

This article was originally published in The Rose Sheet

Executive Summary

Fragrance marketer will offer 4,336,050 shares of its common stock in a public offering, firm says Oct. 10. Selling stockholders are LV Capital USA, Inc. (3,436,050 shares), CEO Jean Madar (450,000 shares) and President Philippe Benacin (450,000 shares), according to Inter Parfums. Madar and Benacin additionally will "grant to the underwriters a 30-day option to purchase up to an additional 650,408 shares of Inter Parfums common stock to cover over-allotments, if any," company notes, adding firm "will not receive any proceeds of the sale of its common stock by the selling stockholders." Offering will be managed by Oppenheimer & Co. and SG Cowen & Co., LLC, with Citigroup Corporate and Investment Banking acting as book runner...

You may also be interested in...



Impella Safety Update: Data Supports Pump For Qualified Patients

Updated data from a postmarket study of Abiomed’s Impella RP right-heart pump further supports the device’s safety for a specific patient population.

Quality, Safety, MDSAP A Focus For Medtech In New USMCA Trade Agreement

The new US-Mexico-Canada (USMCA) trade agreement includes language on enhancing regulatory compatibility between the three countries by recognizing quality systems audits performed under the Medical Device Single Audit Program (MDSAP). It also stipulates that each trading partner “consider its resources and technical capacity” in ensuring the safety, effectiveness and quality of devices – and more. Medtech industry advocacy group AdvaMed is praising the deal, reached by the three countries on 10 December.

Novo Nordisk Targets Smart Insulin, Stem Cell-Therapies

Novo Nordisk’s CEO talks to Scrip about the promise of glucose-responsive insulin, stem cell therapy, and a diabetes landscape without Sanofi.

UsernamePublicRestriction

Register

RS013433

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel